

VASCULARIZATION IN TISSUE ENGINEERING

Editor:
Xiaoxiao Cai

Bentham Books

Vascularization in Tissue Engineering

Edited by

Xiaoxiao Cai

*West China School of Stomatology
Sichuan University
China*

Vascularization in Tissue Engineering

Editor: Xiaoxiao Cai

ISBN (Online): 978-981-14-7584-9

ISBN (Print): 978-981-14-7582-5

ISBN (Paperback): 978-981-14-7583-2

© 2020, Bentham Books imprint.

Published by Bentham Science Publishers Pte. Ltd. Singapore. All Rights Reserved.

BENTHAM SCIENCE PUBLISHERS LTD.

End User License Agreement (for non-institutional, personal use)

This is an agreement between you and Bentham Science Publishers Ltd. Please read this License Agreement carefully before using the book/echapter/ejournal (“**Work**”). Your use of the Work constitutes your agreement to the terms and conditions set forth in this License Agreement. If you do not agree to these terms and conditions then you should not use the Work.

Bentham Science Publishers agrees to grant you a non-exclusive, non-transferable limited license to use the Work subject to and in accordance with the following terms and conditions. This License Agreement is for non-library, personal use only. For a library / institutional / multi user license in respect of the Work, please contact: permission@benthamscience.net.

Usage Rules:

1. All rights reserved: The Work is the subject of copyright and Bentham Science Publishers either owns the Work (and the copyright in it) or is licensed to distribute the Work. You shall not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit the Work or make the Work available for others to do any of the same, in any form or by any means, in whole or in part, in each case without the prior written permission of Bentham Science Publishers, unless stated otherwise in this License Agreement.
2. You may download a copy of the Work on one occasion to one personal computer (including tablet, laptop, desktop, or other such devices). You may make one back-up copy of the Work to avoid losing it.
3. The unauthorised use or distribution of copyrighted or other proprietary content is illegal and could subject you to liability for substantial money damages. You will be liable for any damage resulting from your misuse of the Work or any violation of this License Agreement, including any infringement by you of copyrights or proprietary rights.

Disclaimer:

Bentham Science Publishers does not guarantee that the information in the Work is error-free, or warrant that it will meet your requirements or that access to the Work will be uninterrupted or error-free. The Work is provided "as is" without warranty of any kind, either express or implied or statutory, including, without limitation, implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the results and performance of the Work is assumed by you. No responsibility is assumed by Bentham Science Publishers, its staff, editors and/or authors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products instruction, advertisements or ideas contained in the Work.

Limitation of Liability:

In no event will Bentham Science Publishers, its staff, editors and/or authors, be liable for any damages, including, without limitation, special, incidental and/or consequential damages and/or damages for lost data and/or profits arising out of (whether directly or indirectly) the use or inability to use the Work. The entire liability of Bentham Science Publishers shall be limited to the amount actually paid by you for the Work.

General:

1. Any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims) will be governed by and construed in accordance with the laws of Singapore. Each party agrees that the courts of the state of Singapore shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims).
2. Your rights under this License Agreement will automatically terminate without notice and without the

need for a court order if at any point you breach any terms of this License Agreement. In no event will any delay or failure by Bentham Science Publishers in enforcing your compliance with this License Agreement constitute a waiver of any of its rights.

3. You acknowledge that you have read this License Agreement, and agree to be bound by its terms and conditions. To the extent that any other terms and conditions presented on any website of Bentham Science Publishers conflict with, or are inconsistent with, the terms and conditions set out in this License Agreement, you acknowledge that the terms and conditions set out in this License Agreement shall prevail.

Bentham Science Publishers Pte. Ltd.

80 Robinson Road #02-00

Singapore 068898

Singapore

Email: subscriptions@benthamscience.net



CONTENTS

PREFACE	i
FOREWORD	ii
LIST OF CONTRIBUTORS	iv
CHAPTER 1 BIOLOGICAL BASIS OF VASCULARIZATION	1
<i>Yichen Ge, Yuting Wen and Xiaoxiao Cai</i>	
1. INTRODUCTION OF BIOLOGICAL VASCULARIZATION	1
1.1. Vasculogenesis	2
1.1.1. Embryonic Vasculogenesis	2
1.1.2. Postpartum Vasculogenesis	4
1.1.3. Vasculogenesis in Reparative Process	5
1.2. Angiogenesis	6
1.2.1. Introduction of Angiogenesis	6
1.2.2. Branching, Maturation and Resting of Blood Vessels in Angiogenesis	7
2. BIOLOGICAL MOLECULES	8
2.1. The VEGF Family	8
2.2. PDGF Family	9
2.3. Angiopoietin	10
2.4. The bFGF and The FGF Superfamily	11
2.5. Integrins and Proteases	11
2.6. Junctional Molecules	12
3. THE MARKERS AND TESTING OF ANGIOGENESIS	13
3.1. Markers in Extracellular Matrix	13
3.1.1. Fibronectin	13
3.1.2. Polysaccharide	14
3.1.3. Promoting Factor	14
3.1.4. Related Proteases	16
3.1.5. Specific Substance Produced by Angiogenesis	16
CONSENT FOR PUBLICATION	17
CONFLICT OF INTEREST	17
ACKNOWLEDGEMENTS	17
REFERENCES	17
CHAPTER 2 EFFECTS OF MICROENVIRONMENT FACTORS ON ANGIOGENESIS	23
<i>Changyue Xue and Xiaoxiao Cai</i>	
1. INTRODUCTION	23
2. EFFECT OF EXTRACELLULAR MATRIX ON ANGIOGENESIS IN TISSUE ENGINEERING	24
2.1. Properties of the Extracellular Matrix of Vessels	24
2.2. Role of Matrix Stiffness in Regulating Endothelial Cells Behaviour	26
2.3. Role of Matrix Stiffness in Regulating Angiogenesis	28
2.4. Underlying Mechanism of Matrix Stiffness on Angiogenesis	29
2.4.1. Mechanosensing and Mechanotransduction	29
2.4.2. Expression of Functional Proteins and Growth Factors	31
3. EFFECT OF FLUID SHEAR FORCE ON ANGIOGENESIS	32
4. EFFECT OF MICROPATTERNS OF SUBSTRATE MATERIALS ON ANGIOGENESIS	33
5. EFFECT OF CELL LOADING STRESS ON ANGIOGENESIS	34
6. EFFECT OF NITRIC OXIDE LEVEL ON ANGIOGENESIS	34

CONCLUDING REMARKS	34
CONSENT FOR PUBLICATION	34
CONFLICT OF INTEREST	35
ACKNOWLEDGEMENTS	35
REFERENCES	35
CHAPTER 3 MICROENVIRONMENT OF PATHOLOGICAL VASCULARIZATION	47
<i>Mei Zhang and Xiaoxiao Cai</i>	
1. INTRODUCTION	47
2. PATHOLOGICAL CONDITIONS LEADING TO ADVERSE VASCULARISATION	48
2.1. Inflammation-Related Diseases and Angiogenesis	48
2.1.1. <i>Inflammation-Related Diseases and Angiogenesis</i>	49
2.1.2. <i>Pathological Mechanism of Inflammatory Angiogenesis</i>	49
2.1.3. <i>Consequence of Inflammatory Angiogenesis</i>	50
2.2. Vascularization Under Ischemia	51
2.2.1. <i>Ischemic Diseases and Angiogenesis</i>	51
2.2.2. <i>Pathological Mechanism of Ischemic Angiogenesis</i>	51
2.2.3. <i>Consequence of Ischemic Angiogenesis</i>	52
2.3. Vascularization Under Hypoxia	52
2.3.1. <i>Hypoxic Disease and Angiogenesis</i>	53
2.3.2. <i>Pathological Mechanism of Hypoxic Angiogenesis</i>	54
2.4. Vascularization Under Senility	54
2.4.1. <i>Pathological Mechanism of Aging Angiogenesis</i>	55
2.4.2. <i>The Consequences of Impaired Angiogenesis</i>	56
3. CHARACTERISTICS OF ABNORMAL BLOOD VESSELS	56
3.1. Abnormal Vascular Structure and Dysfunction	57
3.2. Abnormality of Endothelial Cell	57
3.3. Excessive Vascular Permeability	57
CONCLUDING REMARKS	58
CONSENT FOR PUBLICATION	58
CONFLICT OF INTEREST	58
ACKNOWLEDGEMENTS	58
REFERENCES	58
CHAPTER 4 VASCULARIZATION IN CO-CULTURE SYSTEMS	70
<i>Tianyi Zhang and Xiaoxiao Cai</i>	
1. VASCULARIZATION IN PHYSIOLOGICAL AND PATHOLOGICAL CONDITIONS 70	
1.1. Vasculogenesis and Angiogenesis in Healing and Tissue Regeneration	70
1.1.1. <i>Vasculogenesis</i>	72
1.1.2. <i>Angiogenesis</i>	72
2. VASCULARIZATION IN PHYSIOLOGICAL MICROENVIRONMENTS	74
2.1. Vascularization in Bone Injury Sites	75
2.2. Vascularization in Wound Healing	76
3. CO-CULTURE METHODOLOGIES IN TISSUE ENGINEERING	77
3.1. Cells Types for Co-Culture Systems	77
3.1.1. <i>Classified by the Role of Cells</i>	77
3.1.2. <i>Classified by Cells Types</i>	78
3.2. Direct Co-Culture & Indirect Co-Culture	81
3.2.1. <i>Direct Co-Culture System</i>	81
3.2.2. <i>Indirect Co-Culture System</i>	83
3.3. Cellular Interactions in Co-Culture	84
3.3.1. <i>Cell-Cell Adhesion</i>	84

3.3.2. Signaling via Cell-ECM Adhesion	84
3.3.3. Paracrine Signaling Through Soluble Factors	86
3.4. Factors in Co-Culture Systems	86
3.4.1. Culture Media	86
3.4.2. Seeding Methods	87
3.4.3. Extracellular Matrix (ECM)	88
3.4.4. Oxygen Environment	88
3.4.5. 3D Scaffolds	89
3.4.6. Biomechanical Stimulation	89
4. APPLICATIONS OF CO-CULTURE IN VASCULAR ENGINEERING	90
4.1. Bone Tissue Engineering (BTE)	90
4.2. Cardiac Regeneration	91
4.2.1. Use of Endothelial Cells and MSCs	92
4.2.2. Use of Human Pluripotent Stem Cells (HPSCs)	93
4.2.3. Use of Endothelial Cells and Perivascular Cells	93
4.3. Skin Regeneration	93
CONSENT FOR PUBLICATION	95
CONFLICT OF INTEREST	95
ACKNOWLEDGEMENTS	95
REFERENCES	95
CHAPTER 5 ANGIOGENESIS AND MATERIALS	102
<i>Xin Qin, Yuting Wen and Xiaoxiao Cai</i>	
1. INTRODUCTION	102
2. TISSUE ENGINEERING BIOLOGICAL SCAFFOLD MATERIALS	103
2.1. The Design Concept of Ideal Biological Scaffold Material	103
2.2. Classification and Basic Concept of Biological Scaffold Materials	104
2.3. Topological Structure of Scaffold Material	109
3. TISSUE ENGINEERING STRATEGY FOR INDUCING ANGIOGENESIS USING	
BIOLOGICAL SCAFFOLDS	110
3.1. Scaffold-Based Delivery System	110
3.2. Special Treatment of Scaffold Material to Promote Vascularization	111
3.3. Scaffold-Based Cell Complex	113
3.4. Prevascularization to Promote Vascularization of Engineered Tissue	114
4. BIOLOGICAL CONSIDERATION OF SCAFFOLD MATERIALS IN INDUCING	
ANGIOGENESIS	115
4.1. The Outcome of Scaffold Materials in the Process of Vascularization	115
4.2. Modes of Degradation	116
4.3. Factors Affecting the Degradation of Scaffold	120
5. CUTTING EDGE TREND AND DEVELOPMENT OF SCAFFOLD MATERIALS	120
5.1. Shortages of Existing Support Materials	120
5.2. Relevant Frontier Applications	121
CONSENT FOR PUBLICATION	122
CONFLICT OF INTEREST	122
ACKNOWLEDGEMENTS	123
REFERENCES	123
SUBJECT INDEX	130

PREFACE

Angiogenesis refers to the process of forming a new vascular system with an existing vascular network through the proliferation and migration of vascular endothelial cells on the basis of existing capillaries and/or venules. Angiogenesis is of great significance in tissue engineering, wound healing and regeneration repair. The core of tissue engineering is to establish a three-dimensional space complex of cells and biological materials, which is used to reconstruct the morphology, structure and function of the damaged tissues and achieve permanent replacement, to achieve the purpose of repairing wounds and rebuilding functions. However, there are few tissue engineering products that can be applied to clinics at present. One of the main reasons is the early vascularization of tissue engineering products. Evidence shows that when the cell mass is greater than 3 mm^3 , the diffusion of interstitial fluid cannot be used to maintain the cell's survival, and the supply of oxygen and nutrients must be achieved through the regeneration of blood vessels. Because tissue engineering scaffolds do not have a vascular network, vascular regeneration has become an important factor limiting the ability of tissue engineering constructs to form tissues after implantation. Therefore, when using tissue engineering technology to construct large and complex artificial tissues or organs, how to avoid ischemic necrosis or poor healing of the central part of the defect has become the primary task of tissue engineering vascularization. At present, by constructing scaffold material-seed cell-growth factor complex, based on the research foundation of angiogenesis mechanism, the formation of neovascularization *in vitro* three-dimensional microenvironment or *in vivo* transplantation culture is the most common method for tissue engineering vascularization. Therefore, it is very important to understand the occurrence, development, physiological and pathological processes of angiogenesis for tissue engineering vascularization. In this book, the authors focus on the biological and pathological conditions of vascularization, microenvironment factors on angiogenesis, co-culture systems and scaffold materials used for angiogenesis, including: (1) biological basis of vascularization; (2) effects of microenvironment factors on angiogenesis; (3) microenvironment of pathological vascularization; (4) vascularization in co-culture systems; (5) vascularization and scaffold material.

Though this book, readers will have a better understanding of the occurrence, development, physiological and pathological processes of angiogenesis, and know more about ways and means of angiogenesis. The authors sincerely hope that this book will add further insight into basic and applied researchers as well as clinicians involved in tissue engineering vascularization, thus contributing to further advances in regenerative medicine.

Xiaoxiao Cai

Professor of West China School of Stomatology
Sichuan University
Vice-director of Dental Implant Center
West China Hospital of Stomatology
No. 14, 3rd Sec
Ren Min Nan Road
Chengdu 610041
P.R. China

FOREWORD

When Dr. Cai asked me to write this foreword, I was greatly honored to have the opportunity to introduce this eBook.

As one of the research hotspots of life science in the 21st century, tissue engineering is a new subject combining cell biology and material science to construct tissue or organs *in vitro* or *in vivo*. The method is to plant seed cells on scaffold materials to form an active complex, which finally establishes tissues and organs with normal physiological functions and is applied to the treatment and repair of human diseases. At present, the construction of skin, bone and cartilage *in vitro* has made great progress, and has been widely used in clinical. However, how to build a blood supply system that can transport nutrients, oxygen and remove metabolize waste for the body, to ensure the survival of implanted artificial tissue in the body and play its normal physiological function, which is a major difficulty of tissue engineering, as well as a key issue of regenerative medicine.

Vascularization, existing in both physiological and pathological procedures, is a considerable complicated process which is regulated and controlled by a variety of biological factors via diverse pathways and mechanism. It's a complex and multi-step physiological process, which must be carried out under a strict micro-environment. At present, in addition to conventional treatment methods, plenty of vascular diseases such as arterial ischemic disease, peripheral arterial disease, pulmonary hypertension, limb ischemia, myocardial infarction and cerebral infarction were treated with endothelial progenitor cells possessing the characteristics of stem cells in clinical work, which have a very broad prospect. Therefore, the exploration of the vascularization of tissue engineering will greatly promote the research results of regenerative medicine to clinical application.

It is generally known that seeding cells, growth factors, scaffold materials and microenvironment are the four basic elements of tissue engineering. This eBook is a comprehensive and systematic introduction to the vascularization of tissue engineering from these four aspects. Firstly, it details the whole process of physical vascularization (vascularization and angiogenesis) and the role of various growth factors. Then, the effect of the physiological microenvironment and pathological microenvironment on the vascularization in tissue engineering is elaborated, such as related mechanism, pathophysiological features and so on. Besides that, various common seeding cells, typical co-culture system model and multifarious scaffold materials of vascularization in tissue engineering are also introduced in detail.

In conclusion, I am excited about this eBook. Because it not only systematically and comprehensively introduces the mature theoretical knowledge, methods and technology of vascularization in tissue engineering, but also shows the latest progress achievements and future development in the world. I believe it will be beneficial to all those who have an interest in vascularization in tissue engineering and will lay a crucial and solid theoretical foundation for making future progress of tissue engineering vascularization.

Yunfeng Lin

Professor of Department of Oral and Maxillofacial Surgery
West China College of Stomatology
Sichuan University

Vice-director of State Key Laboratory of Oral Diseases
Director of Laboratory for Nucleic Acid Nanomaterials, SKLOD
Executive Editor-in-Chief of Bone Research
Deputy Editor-in-Chief of Cell Proliferation
China

List of Contributors

Changyue Xue	State Key Laboratory of Oral Diseases, Chengdu, China
Mei Zhang	State Key Laboratory of Oral Diseases, Chengdu, China
Tianyi Zhang	State Key Laboratory of Oral Diseases, Chengdu, China
Xiaoxiao Cai	State Key Laboratory of Oral Diseases, Chengdu, China
Xin Qin	State Key Laboratory of Oral Diseases, Chengdu, China
Yichen Ge	State Key Laboratory of Oral Diseases, Chengdu, China
Yuting Wen	State Key Laboratory of Oral Diseases, Chengdu, China

Biological Basis of Vascularization

Yichen Ge, Yuting Wen and Xiaoxiao Cai*

State Key Laboratory of Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, China

Abstract: Vascularization, existing in both physiological and pathological procedures, is a considerable complicated process which is regulated and controlled by a variety of biological factors *via* diverse pathways and mechanism. It is crucial to understand these processes and factors well if we intend to unveil the mystery of vascularization. More importantly, understanding basic processes offer tools and thinking directions with which researchers are able to design various methods to achieve vascularization, which is called vascular tissue engineering. In this part, major procedures of physical vascularization (vasculogenesis and angiogenesis) and growth factors are introduced, as well as their roles and new research outcomes in vascularization. These factors include vascular endothelial growth factor(VEGF), basic fibroblast growth factor(bFGF), platelet-derived growth factor(PDGF), angiopoietin1, angiopoietin2 and others(junctional molecules, integrals *etc.*). Lastly, some frequently used markers and testing methods about vascularization research are briefly introduced.

Keywords: Angiopoietin, Angiogenesis, FGF, PDGF, Vascularization, VEGF.

1. INTRODUCTION OF BIOLOGICAL VASCULARIZATION

It is generally acknowledged that the mechanism of neovascularization comprises two aspects---vasculogenesis and angiogenesis [1, 2]. Supposed as the main mechanism of the construction of vascular networks in the embryonic stage, vasculogenesis occurs in the bone marrow as endothelial progenitor cells (EPCs) gradually migrating, differentiating and finally reforming new vessels, besides it also exists in adult tissue especially in the ischemic area [3, 4]. In the embryo, the first vascular network is built when somites beginning to form by the process of vasculogenesis. Locating between two germ layers, the first blood islands which form the inner layer of the yolk sac occur by *in situ* differentiation from the extra-embryonic mesoderm. In the embryonic stage, vascular network remodeling is characterized as the change of number and/or location of vascular segments to

* Corresponding author Xiaoxiao Cai: Sichuan University, West China School of Stomatology, China; E-mail: xcai@scu.edu.cn

improve functional adaptability without evident network expansion. Vascular fusion can reduce the number of vascular segments and therefore give rise to larger vessels. Larger vessels in other regions are remodeled into a network of smaller vessels which subsequently increase the number of vessels segments. These biological processes result in a big transformation of primary plexus to enter into a more complexly structured secondary stage. Further expansion of primary and secondary vascular plexus during postnatal life occurs with the process of angiogenesis. Angiogenesis generally refers to the process of new blood vessels formation based on pre-existing ones (Shown as Fig. 1a-c). The process of angiogenesis comprises two distinct mechanisms, sprouting of endothelial cells (ECs) and splitting of vessel lumens by intussusceptive microvascular growth (IMG).

1.1. Vasculogenesis

1.1.1. Embryonic Vasculogenesis

Vasculogenesis is a process in which blood vessels differentiate from *in situ* into ECs. Initially, the term was used for embryonic development and the presence of angioblasts, which were entirely associated with prenatal growth. "Vasculogenesis" was first brought out by Werner Risau [5] to term the development of mesodermal vascular plexus by differentiation of vascular fibroblasts. Angioblasts are thought to accumulate in the angiogenesis area. Vasculogenesis that occurring embryogenesis and extraembryonic are often accompanied by hematopoiesis, thus the term "angioblasts" has also been proposed. Elementary observations in Sabin [6] strongly suggest that both hematopoietic cells and ECs origins from the angioblasts. The existence of hemangioblasts *in vivo* has developed. At present, instead of defined as an actual ordinary cell precursor, it's rather more like a competitive cell that can generate hematopoietic cells and ECs to local environmental signals [7].

In early mouse embryos, angioblasts originated from decentralized progenitors in the lateral plate mesoderm and expressed Flk-1 (VEGFR-2) and Brachyury (Bry) genes in turn [8]. Bry gene was inhibited and Flk-1 was activated as development progressed. The dynamic changes of these progenitor cell differentiation markers were as follows: Bry +/Flk-1 -, Bry-/ Flk-1 -, Bry +/Flk-1-, Bry +/Flk-1 -, and Bry +/Flk-1 -. These groups represent different phases of differentiation of vascular mother cells. In addition to Flk-1 and Bry genes, they also display diverse sequences of other genic groups [9]. The existence of vascular mother cells has been verified *in vitro* though collecting endothelial and hematopoietic descendants of colony-forming cells (CFCs) derived from embryoid [10, 11]. Embryoid bodies obtained from suspension cultured embryonic stem cells established a model that simulates many cell differentiation

in multi-aspect during early somatic embryogenesis [12]. *In vitro*, fast breeding CFCs that produce hematopoietic colonies functioned equally to vascular mother cells. The vascular mother cells have multi-directional differentiation potentials to form ECs, smooth muscle cells and hematopoietic cells under specific conditions [8, 9, 11]. The commitment of angiogenic cells is controlled by transcription factor of *etv2/er71* gene, the upstream of core genes in the development of EC lineage [13], and activation of endothelial cell line specific genes (endothelin, endothelin and VE cadherin) and hematopoietic and/or hematopoietic (hematopoietic, hematopoietic and SCL) lineages [14]. *ETv2* guide differentiation of endothelial and hematopoietic lineage *via* regulating ETS associate genes necessary for downstream stimulation of hematopoietic and endothelial differentiation [14].

Members of the TGF-beta superfamily participated in mesoembryonic expression of *Bry*, for instance BMP (bone morphogenetic protein) and lymph node and activin signals, as a guide between self-renewal of pluripotent stem cells [15, 16]. Fibroblast Growth Factor-2 (FGF-2) and BMP4 are key signaling ingredients that stimulate the development of embryonic mesoderm, thus accelerate ECs and blood cells production [17, 18]. *TFIIS*, subtype of *TCEA3* which express in mesoderm was proved to drive the production mesoderm EC. As shRNA transfection reduced the expression of *TCEA3* in mouse embryonic stem cells, the expression of *Bry* marker in mesoderm increased, the expression of multipotent genes in mesoderm decreased, the differentiation of EC boosted and the production of vascular endothelial growth factor (VEGF) A increased [19]. Therefore, ECs can bypass a hemangioblast intermediate directly from mesodermal angioblasts. EC differentiation in the period of embryonic process has been demonstrated to be produced by vascular mother cells directly from the mesoderm [20, 21]. These ECs can further form tubules during mesoderm culture *in vitro*. Although current evidence supports the existence of angioblasts, it has been a challenge to isolate these cells and determine their exact location in developing embryos.

Embryonic EC are considered be descendants of angioblasts [22]. Angioblasts were found to transform phenotype in mice: initially expressed *tal-1/flk-1*, then *CD31* was obtained, while the expression of *tal-1* was reduced [21]. This phenotypic change of angioblasts was observed during the formation of cardiac ducts, dorsal aortas, interlaminar vessels and main veins in different embryos. During these events, cells processes migration, isolation and assemble into tube/vessel as they differentiate into mature ECs. Instead of classical growth factors such as platelet-derived growth factor (PDGF), VEGF and FGF, notch and *ephb2/ephb4* signaling pathways was considered the key components to regulate dorsal aortic angiogenesis [23, 24]. It has been proved that basement-membrane

Effects of Microenvironment Factors on Angiogenesis

Changyue Xue and Xiaoxiao Cai*

State Key Laboratory of Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, China

Abstract: Angiogenesis is a vital step for complete organ engineering, and the microenvironment is one of the four basic elements of tissue engineering. Microenvironment factors such as oxygen content and stress are key dynamic factors that can trigger the variations of angiogenesis. We may induce the formation of beneficial blood vessels and prevent the formation of pathological blood vessels by precisely regulating the microenvironment. In this chapter, we will elaborate the interaction between vascular endothelial cells and the extracellular microenvironment and summarize the influence of various microenvironment factors on angiogenesis. The finding that microenvironment factors play such a concerted role in angiogenesis suggests that incorporating microenvironment factors into tissue engineering might accelerate the development of novel therapeutics.

Keywords: Angiogenesis, Endothelial cell, Extracellular matrix, Microenvironment, Stiffness.

1. INTRODUCTION

Regenerative medicine technology is one of the most effective and promising methods to repair tissue trauma and function reconstruction. However, the researching results that can be transferred into clinical practice are extremely limited. The lack of nutrition and oxygen supply will lead to the failure of transplantation therapy. In this regard, researchers proposed several schemes that can promote the vascularization of tissue engineering products, including directly inoculating endothelial cells (ECs) onto scaffold materials to generate vascular structure before implantation. However, vascular structure in function was still very limited, for the reason that the scaffold material could not provide the appropriate microenvironment for the growth of related cells and new vessels.

* **Corresponding author Xiaoxiao Cai:** Sichuan University, West China School of Stomatology, China; E-mail: xcai@scu.edu.cn

Endothelial cells (ECs) are the vascular network's basic units, which constitute the lining of blood vessels throughout the body to the fine vascular networks which perfuse all tissues [1]. ECs line vessel walls as a monolayer by adhering to the basal lamina [2]. The vessels in different tissues and organs range in diameter from approximately 8 μm for capillaries to 2.5 cm for the aorta [3]. The microvasculature system comprises only the intima and specialized SMCs, which offer both stability [4] and quiescence to capillaries [5]. As a result of their distinctive location between the volatile, intricate vascular wall and the flowing blood, ECs are subjected to forces from extracellular matrix (ECM) layers as well as surrounding tissues, such as muscle-mediated vessel contraction, physical forces from the residual hoop stress of the vessel wall, and physical inputs that originate from local ECM, which can impinge on the vessels [6]. Taken together, these microenvironment factors have a central role in managing physiological and pathological-related EC behavior, from the molecular to the tissue level.

EC is the basic unit of cell-based support therapy for cardiovascular and ischemic diseases. Guiding ECs biological behavior and optimizing angiogenesis by regulating the microenvironment factors has a great potential value in the treatment of vascular diseases, tumor diseases and so on. In this chapter, the effects of microenvironment factors on the angiogenesis in tissue engineering will be summarized.

2. EFFECT OF EXTRACELLULAR MATRIX ON ANGIOGENESIS IN TISSUE ENGINEERING

2.1. Properties of the Extracellular Matrix of Vessels

The ECM, composed of different functional proteins, is a highly dynamic structure which exists in all tissues and sustains continuous regulated remodeling. The remodeling is carried out by specific enzymes, such as metalloproteinases, accompanied by ECM degradation [7]. The ECM interacts with local cells to mediate various functions, such as proliferation, migration, and autophagy. ECM remodeling has a profound influence on the morphogenesis of cells and their functions [8]. Many pathological states, such as fibrosis or invasive cancer, are accompanied by dysregulation of the ECM structure, composition, abundance, and stiffness. It is imperative for researchers to obtain a thorough understanding of the way that ECM affects organ structure and function, and the way that ECM remodeling influences cell behavior and disease progression.




Fig. (1). FAs are ideal checkpoints which control inside-out and inwards transduction of biomechanical signals of the extracellular matrix.

The ECM of vessels is a network consisting of fibers and pores lined in an isotropic manner, ranging in size from the nanoscale (1–100 nm) to the submicron level (100–1000 nm) [9]. The local stiffness of the ECM has been reported to be between 5–140 kPa. The stiffness of the ECM plays a concerted role in vascular assembly and maintenance, even at the microvasculature level. In pathological conditions, ECM has been proved to have thickened in a number of tubes [10]. Moreover, ECs function is significantly affected by the elasticity of their local surrounding ECM, which provides matrix and stability for angiogenesis [11]. ECs have also been shown to secrete certain ECM components, which increase overall vessel rigidity in many pathological states [12]. Located basolaterally to all EC monolayers [13], the local ECM is a heterogeneous and complicated mixture of laminin; fibronectin; enactin; nidogen; collagen IV and V; the heparin-sulfate

Microenvironment of Pathological Vascularization

Mei Zhang and Xiaoxiao Cai*

State Key Laboratory of Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, China

Abstract: Past studies have shown that many destructive diseases drive abnormal angiogenesis and progression, such as inflammatory diseases, cancers, rheumatoid arthritis, and atherosclerosis diseases. These diseases, which have a variety of consequences, show some common pathophysiological characteristics, among which the proliferation of endothelial cells, recruitment of immune cells, and high-expression of angiogenic factors play a key role. At the same time, local hypoxia, inflammation, senile, and local ischaemia cause adverse consequences such as abnormal vascularisation. Abnormal blood vessels usually include vascular structural abnormalities, abnormal endothelial cells, excessive vascular permeability, vascular dysfunction, *etc.* The pathological microenvironment is related to abnormal vascularisation and further aggravates the abnormality of vascularisation. Therefore, this review will be helpful for further study of vascularised tissue engineering.

Keywords: Angiogenesis, Ageing, Inflammation, Ischemia and Hypoxia, Pathological Vascularization.

1. INTRODUCTION

Angiogenesis, the formation of new blood vessels from pre-existing vessels, is necessary for various physiological processes. During evolution, blood vessels emerge, and transport oxygen and nutrients to the distant tissues and organs [1]. Undoubtedly, these blood vessels are essential for the growth of tissues in embryos and repair of injured tissues in adults. However, the imbalance of vascular growth leads to many diseases. Similarly, the pathological microenvironment of these diseases also accelerates the formation of abnormal blood vessels [2, 3]. As a matter of fact, pathological angiogenesis is a marker of malignant tumours, and various metastatic, ischaemic, and inflammatory diseases [4]. The pathological microenvironment of vessels is a dynamic network, which is composed of many factors.

* Corresponding author Xiaoxiao Cai: Sichuan University, West China School of Stomatology, China; E-mail: xcai@scu.edu.cn

Microenvironment has an increasingly significant effect on angiogenesis under the conditions of diseases. On the other hand, angiogenesis is a marker of growth, invasion, and metastasis of malignant diseases. Increasing studies have shown that the microenvironment of diseases is closely related to pathological angiogenesis. In this review, the effects of the microenvironment of tumours, and various metastatic, ischaemic, and inflammatory diseases on angiogenesis are analysed in detail to provide a broader idea for angiogenesis research, especially for understanding angiogenesis in tissue engineering.

2. PATHOLOGICAL CONDITIONS LEADING TO ADVERSE VASCULARISATION

Pathological angiogenesis is a sign of cancers and various ischaemic and inflammatory diseases [4], as shown in Fig. (1). By exploring the formation of abnormal blood vessels, their mode of action, the key molecules, and microenvironments involved, and related studies, it would help us understand the occurrence and development of cancers, and ischaemic, and inflammatory diseases [5, 6]. During evolution, blood vessels emerge and then transport oxygen and nutrients to distant tissues [7, 8]. Undeniably, these blood vessels are essential for sustaining the growth of normal and injured tissues. However, abnormal, excessive, and insufficient vascular growth is usually involved in the pathogenesis of many diseases [2]. After birth, angiogenesis continues to play a significant role in organ growth. While the growth of blood vessels is stationary in adulthood, angiogenesis occurs only during pregnancy [1]. Nevertheless, endothelial cells manifest their remarkable divisive capacity in the face of pathological stimulation, such as vascular hypoxia and lymphangitis [9]. During healing and repair of wound, angiogenesis is reactivated. However, in several other diseases, excessive stimulus can break out the balance between stimulants and inhibitors, which lead to abnormal angiogenesis [10]. The most common conditions for activation of abnormal angiogenesis are inflammatory diseases and malignant tumours, however, other diseases can also have an impact, such as asthma, obesity, cirrhosis of the liver, diabetes, endometriosis, AIDS, multiple sclerosis, autoimmune diseases, and bacterial infections [1, 11].

2.1. Inflammation-Related Diseases and Angiogenesis

Angiogenesis participate in the occurrence and progression of many destructive diseases, such as cancers, atherosclerosis, inflammatory bowel disease [IBD], and rheumatoid arthritis [12]. Angiogenesis is regulated by different types of cells in its microenvironment, such as immune cells [13 - 16]. During inflammation, both endothelial and parietal cells are involved in the migration of white blood cells to

inflammatory centres [17, 18]. Immune cells participate in wound healing by controlling the formation of new blood vessels. Emerging research has shown that these cells are involved in promoting angiogenesis and vascular remodelling in ischaemic injury, cancers, and wound healing [19, 20]. These immune cells promote angiogenesis under the strong influence of their microenvironment, especially the inflammatory microenvironment [21].

2.1.1. Inflammation-Related Diseases and Angiogenesis

Moderate inflammation is important for maintaining homeostasis [22], but severe and persistent inflammation leads to some chronic inflammatory diseases, such as cancers [21], atherosclerosis [23], IBD, and rheumatoid arthritis [24]. Hypoxia-inducible factors [HIFs] are produced by inflammatory tissues, which are finished by activating endothelial cells, macrophages, and fibroblasts due to local hypoxia [25 - 27]. Long-term infiltration of these factors leads to adhesive degradation of endothelial cells and microvascular instability [28, 29]. On the other hand, it is beneficial to the proliferation and migration of endothelial cells and angiogenesis [30, 31].

Although these diseases develop differently and have different clinical manifestations, they have the same pathophysiological peculiarity, among which enhanced vascular permeability, macrophage polarization, and monocyte recruitment play essential roles [12]. Tumour-associated macrophages [TAM] excrete some angiogenic growth factors and proteases, which include vascular endothelial growth factor [VEGF], to promote angiogenesis and further migration and infiltration of tumours [32 - 34]. Atherosclerotic plaque can be formed by some proteolytic enzymes, which are secreted by macrophages, including matrix metalloproteinases [MMPs] [35]. Similar to angiogenesis of tumours, neovascularisation is mediated by macrophage-derived angiogenic factors in atherosclerotic plaques [36]. Other inflammatory diseases function similarly. Local hypoxia and increased vascular permeability caused by inflammation lead to new angiogenesis. During this period, the related pro-inflammatory factors and angiogenic factors secreted by macrophages play a key role.

2.1.2. Pathological Mechanism of Inflammatory Angiogenesis

First, aggregation of immune cells plays an important role in the process of inflammatory angiogenesis. Immunocytes associated with angiogenesis include natural killer cells, neutrophils, dendritic cells, eosinophils, mast cells, macrophages, and T cells [37]. It has been reported that angiogenesis is induced by macrophages in wounds and tumours, which stimulate ischaemia-induced

Vascularization in Co-Culture Systems

Tianyi Zhang and Xiaoxiao Cai*

State Key Laboratory of Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, China

Abstract: Since endothelial cells are not able to create capillaries by themselves, proangiogenic factors are indispensable for endothelial cells to migrate and form microcapillaries. Thus, exogenous proangiogenic compounds are needed to improve the formation of microcapillary-like structures. Multiple forms of cell-cell interactions could result in the production of essential proangiogenic factors in co-culture systems. Many studies have examined that the co-culture systems of endothelial cells and other cell types, such as osteoblasts or mesenchymal stem cells (MSCs), can facilitate the formation of capillary-like structures. The focus of this chapter is threefold: (1) Informing the biological function of vascularization in the physiological environment. (2) Introducing typical co-culture system models for vascularization. (3) Identifying the proangiogenic factors that play crucial roles in the formation of capillary-like structures.

Keywords: Biomechanical Stimulation, Bone Tissue Engineering, Cardiac Regeneration, Cell-ECM Adhesion, Cellular Interactions, Co-culture, Cell-cell Adhesion, Direct co-culture, Endothelial Cells, Extracellular Matrix, Indirect co-culture, Media, Mesenchymal Stem Cells, Osteoblast, Oxygen Environment, Scaffolds, Seeding Methods, Skin Regeneration, Soluble Factors, Vascularization.

1. VASCULARIZATION IN PHYSIOLOGICAL AND PATHOLOGICAL CONDITIONS

1.1. Vasculogenesis and Angiogenesis in Healing and Tissue Regeneration

Vascular networks consist of two fundamental mechanisms: vasculogenesis and angiogenesis. The former is the vascular regeneration and the formation of capillary plexus *via* endothelial progenitor cells (EPCs). The latter indicates the generation of new vessels from the preexisting vascular network, involving capillary sprouting and remodeling.

* Corresponding author Xiaoxiao Cai: Sichuan University, West China School of Stomatology, China; E-mail: xcai@scu.edu.cn




Fig. (1). Vasculogenesis.

Vascular systems play crucial roles in an abundance of biological processes, including metabolism [1], development [2], immunity [3], healing [4], and regeneration, as well as the progression of many diseases. Transporting oxygen and nutrients and removing metabolic waste, vessels are essential for growth and development. They promote the circulation of immune cells and rapidly deliver them to surrounding tissues when necessary. The versatility of vascular networks stems from the meshwork and the multiple cell types that make up blood vessels. Vessels are composed of endothelial lining surrounded by perivascular cells (PVCs) (smooth muscle cells and pericytes) and extracellular matrix (ECM) [5]. What is more, ECM is of paramount importance for normal vascular function.

Vascular networks consist of different forms of vessels: arteries, arterioles, capillaries, venules, and veins. Blood rushes from the heart into main arteries, then branches out into small arteries and flows in small arteries and capillaries. In the process of returning to the heart, blood flows through capillaries, tiny veins (venules), veins, and cavity veins. Capillaries connect small arteries and venules. The permeability of the capillary walls allows oxygen delivery and metabolic

exchange. Therefore, the function of transforming nutrition and oxygen to tissues is performed mostly by microvascular networks, which encompasses small arteries, capillaries, and small veins [6].

1.1.1. Vasculogenesis

Vasculogenesis is the initial formation of vessels by cells differentiating into endothelial cells *in situ*. The process is only related to embryonic life previously, while recent studies have reported that vasculogenesis also occurs in adult tissues. The process involves angioblasts and endothelial progenitor cells.

Angioblasts, which are considered to be precursors of embryonic endothelial cells, are recruited during embryonic and fetal growth. They migrate, separate, and finally assemble into vessels, simultaneously differentiating into mature endothelial cells. Phenotypes of angioblasts change during the cardiovascular, aortic, and venous formation of embryos among multiple species [7].

EPCs usually exist in post-natal vasculogenesis, including healing, ischemia, atherosclerosis, myocardial infarction, and tumor growth. Fig. (1) shows the involvement of EPCs in vasculogenesis. During permanent wound healing and inflammatory reactions, such as obesity, atherosclerosis, hypercholesterolemia, and diabetes, the vasculature is distorted and confused—the phenomenon associated with a lower quantity of cEPCs (circulating endothelial progenitor cells). Vascular dysfunction manifests as a lower response to growth factors/chemokines [8]. Besides, the addition of EPCs to the injured vessel wall leads to vascular re-endothelialization. Another way to achieve re-endothelialization is colonization and re-endothelialization of cEPCs in the implanted biomaterials, which is also a hope for future therapy [9].

Neovascularization is essential to transport proteins and cells to injury sites and plays a critical role in tissue repair, growth, and development.

1.1.2. Angiogenesis

Angiogenesis refers to the formation of microvessels from existing blood vessels and capillaries through elongation, inosculation, intussusception, or sprouting.

Inosculation is vital for establishing a connection between the transplanted vascular network and the host microcirculation network. Intussusception involves bifurcation of vessels, which remodels the existing vasculature by the protrusion and fusion of opposing vessel walls in the lumen (See Fig. 2). Compared with sprouting, intussusception angiogenesis is considerably swift in the expanded

Angiogenesis and Materials

Xin Qin, Yuting Wen and Xiaoxiao Cai*

State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, China

Abstract: In the process of tissue engineering vascularization, as one of the three major factors of tissue engineering, scaffold materials play a vital role in the various processes of vascularization. As a starting point, this chapter first introduces the reader to several strategies for scaffolding materials to promote vascularization. It basically describes the reasons for the use of scaffold materials in vascularization and the necessity of scaffold materials in tissue engineering vascularization. Then we will focus on how to properly use the scaffold material. The design of the scaffold material itself is a key factor in the function of the material, and the scaffold material with ideal biological properties can make the process of vascularization more effective. Factors such as the topology of the material and the physical and chemical properties of the material affect the success rate of vascularization to varying degrees. We hope that readers can obtain the basic knowledge and principles of stent design from this chapter. Finally, a number of fresh ideas have emerged for the design of tissue engineered vascular materials, such as new material handling methods, new ways of combining cells, and so on, which have improved the vascularization process to varying degrees. Scaffold materials have shown attractive prospects and great possibilities in vascular tissue engineering. Previous studies have found many materials associated with vascularization, but there are also many problems to be solved. With the development of materials science and engineering, it is believed that there will be new vascular stent materials with better performance and more suitable for vascularization in the future.

Keywords: Angiogenesis, Degradation Modes of Scaffold, Materials, Tissue Engineering Vascularization.

1. INTRODUCTION

With the development of tissue engineering technology, repairing large-area bone defects using tissue-engineered bone has become a widely used approach. The scaffold materials with good three-dimensional structures can promote cell growth and proliferation and tissue ingrowth, and a variety of materials can reach a combined effect to meet the clinical demand.

* Corresponding author Xiaoxiao Cai: Sichuan University, West China School of Stomatology, China; E-mail: xcail@scu.edu.cn

In addition, it is important to actively seek new material preparation technology and improve the existing methods, in order to create an excellent scaffold. However, vascularization is still a major challenge for bone tissue engineering.

2. TISSUE ENGINEERING BIOLOGICAL SCAFFOLD MATERIALS

The ideal healthy blood vessels in tissue engineering should have the following conditions: They should possess the ability to or simulate *in vivo* conditions. There are three layers of vascular wall structure, namely adventitia, media, and intima. They should exhibit biocompatibility, that is to say, it is not easy to produce thrombus and immune rejection. At the same time, it has similar biological characteristics with normal blood vessels, such as relaxation response to drug stimulation and needs to possess the mechanics exhibited by blood vessels. Third, it should also exhibit viscoelasticity and can withstand certain pressure. Scaffold materials are indispensable for achieving good vascularization processes.

With the continuous development of tissue engineering, repairing large-area bone defects using tissue-engineered bone has become a widely used approach. The scaffold materials with good three-dimensional structures can promote cell growth and proliferation, tissue growth, osteogenesis, and vascularization. Each scaffold has its own inadequacies; therefore, the combination of a variety of materials can achieve a combined effect to meet the clinical demand. In addition, it is important to actively seek new material preparation technology and improve the existing methods, in order to create excellent scaffolds [1 - 4].

2.1. The Design Concept of Ideal Biological Scaffold Material

Vascular stent materials play an indispensable role in vascular tissue engineering. The desired support for the growth of cells *in vitro*, which can provide the organization of blood vessels, certain mechanical strength and mechanical properties, seed cell growth. The ideal stent should have the following properties: (1) Controllable rate of biodegradation; (2) low immunogenicity, which does not cause an inflammatory response; (3) good biological properties; (4) good mechanical and physiological properties; (5) suitable porous structure; and (6) they should be easy to process and sterilize [1]. In short, it is necessary to provide specific three-dimensional (tubular) scaffolds for the construction of tissue-engineered blood vessels, which can be used as matrix materials for the implantation of vascular cells, so that the inoculated cells can be positioned, attached, and localized growth and proliferation can be promoted. Meanwhile, the materials can arrange the cells in the space of scaffolds, differentiate with specific functions, and synthesize appropriate extracellular matrix, following which tissue-

engineered blood vessels can be transplanted. *in vivo* stent materials should also have strong learning support and anti-blood pressure functions [2, 5 - 7].

2.2. Classification and Basic Concept of Biological Scaffold Materials

Currently used vascular stent materials include natural biological stent materials, synthetic biodegradable polymer materials, composite materials, and nanomaterials (Table 1).

Table 1. Comparison of various scaffolds materials.

Material Classification	Natural Scaffold Materials	Synthetic Biomaterials	Nanomaterials
Material composition	Macromolecular materials such as collagen, alginate, <i>etc.</i> ; acellular tissue matrix materials such as acellular dermal matrix, acellular vascular matrix, acellular bladder matrix, <i>etc.</i>	Non degradable polymer materials: Polyester and expanded polytetrafluoroethylene; degradable polymer materials: Poly (β - hydroxybutyric acid), poly (aminic acid), polycarbonate, polyurethane, poly (lactic acid) (poly (L-lactic acid, poly (dextran lactic acid, poly (lactic acid)) poly (glycolic acid) (combination of the two, poly (lactic acid and poly (glycolic acid))	Constructed by electrospinning, self-assembly, phase separation, <i>etc.</i>
Advantages	It comes from organism, with high biocompatibility, compliance and low immune rejection	Adjustable microstructure, surface morphology, mechanical properties and degradation rate Degradable cycle, eventually converted to water and carbon dioxide, easy to process	Provide a controllable environment for cell proliferation and directional differentiation, and significantly improve antithrombotic function
Disadvantages	Lack of ability to control extracellular matrix deposition and construction, with the potential risk of transmission of related animal origin pathogens	The synthesis technology is high and expensive, lacking special biological signal or functional group	The synthesis technology is high and expensive, lacking special biological signal or functional group

Natural biological scaffolds are derived from organisms and can be divided into macromolecular unstructured materials and acellular matrix scaffolds. The former includes chitosan, alginate, collagen, gelatin, and hyaluronic acid while the latter includes acellular dermal matrix, acellular small intestinal submucosa, SIS, and acellular vascular matrix. This kind of biomaterial has a strong affinity toward

SUBJECT INDEX

A

- Acid 16, 26, 104, 106, 110, 112, 116, 117
 - aminic 104
 - dimethacrylic 112
 - glycolic 104, 116
 - hyaluronic 14, 93, 104
 - hydroxybutyric 104
 - lactic-co-glycolic 116
 - nucleic 110
 - polyacrylamide 26
 - polyamino 106
 - polyglycolic 106
 - polylactic 106
- Actin filaments 27
- Activation 3, 8, 30, 48, 51, 53, 110, 117
 - of VEGFR-2 mutation 8
- Actomyosin motors 30
- Acute leukaemia 56
- Adenovirus transfection 107
- Adipose-derived stem cells (ADSCs) 86
- Aging 53, 54, 55, 56
 - mitochondrial 56
- Aging Angiogenesis 55
- Amino acid residue sequence 105
- Amplification, large-scale 78
- Angioblasts 2, 3, 6, 72
 - mesodermal 3
- Angiogenesis 1, 3, 4, 6, 8, 9, 11, 13, 14, 15, 16, 23, 31, 32, 34, 47, 48, 49, 50, 51, 52, 53, 54, 56, 57, 58, 72, 74, 94, 111, 121
 - abnormal 47, 48, 50, 57, 58
 - and materials of angiogenesis 121
 - block 11
 - collateral 53
 - compensatory 52
 - conditions for 16
 - dorsal aortic 3
 - early embryonic 8
 - early stage of 13, 50
 - excessive 58
 - growth factors 74
 - inflammatory 49, 50
 - inhibited 94
 - intussusception 72
 - ischaemia-mediated 52
 - modulate 111
 - pathological 8, 9, 47, 48, 58
 - promoting 49, 53
 - related growth factors 31
 - sprouting 15
 - stimulated 4
 - stress-induced 52
 - target 8
 - tumor 14
- Angiogenic cells 3, 114
 - inoculate 114
- Angiogenic factors 16, 47, 49, 50, 52, 53, 75, 111, 113
 - macrophage-derived 49
 - paracrine 113
 - secretion of 16, 111
- Angiogenic 7, 27, 49, 50, 54, 87, 88, 110
 - genes 54, 88
 - growth factors 49, 87, 110
 - molecules 7, 50
 - network 27
- Angiogenic peptides 55
 - secreted 55
- Anti-blood pressure functions 104
- Apoptosis 55, 56
- Applied 87, 114
 - endothelial supplements 87
 - microvascular fragments 114
- Arteriogenesis 6, 50, 51
- Arthritis 58
- Atherosclerosis 6, 47, 48, 49, 51, 53, 72
 - diseases 47
- Atherosclerotic plaque 49, 58
- Atomic force microscopy (AFM) 27

B

- Biological Scaffold Materials 104
- Biomaterials 104, 105, 106, 107, 109, 112, 120
 - biodegradable macromolecule 106
 - natural 105, 107, 112, 120

Xiaoxiao Cai (Ed.)

All rights reserved-© 2020 Bentham Science Publishers

- synthetic 104, 107
 - Biopsy specimens 14
 - Bladder defect repair 111
 - Blood 4, 32, 78, 80, 115
 - peripheral 4, 115
 - umbilical cord 4, 78, 80
 - brain barrier (BBB) 10
 - cells production 3
 - flow perfusion 115
 - perfusion 93
 - Blood vessels 6, 7, 9, 10, 12, 14, 15, 32, 33, 47, 48, 51, 52, 53, 80, 90, 91, 103, 109
 - co-selectively 6
 - density 91
 - development 6, 9
 - formation 80, 109
 - in Angiogenesis 7
 - influence 51
 - Bone 6, 9, 31, 75, 78, 79, 86, 88, 89, 90, 91, 102, 103, 107, 109, 112, 115, 118
 - defect repair 90
 - density 91
 - development 88
 - formation 75, 78, 90, 91
 - injury sites 75
 - regeneration 75, 81, 91, 109, 112
 - tissue-engineered 102, 103
 - vascularized 89
 - Bone marrow (BM) 1, 4, 5, 6, 7, 12, 15, 78, 115
 - cells 7
 - derived 4
 - derived cells (BMDC) 6
 - progenitor cells 12
 - Bone repair 11, 75, 79, 89
 - natural 75
 - Bone tissue 75, 79, 80, 81, 90, 103, 112, 114, 115
 - engineered 115
 - implanted 75
 - regenerate 75
 - tissue-engineered 112
 - Bone tissue engineering (BTE) 70, 75, 79, 80, 81, 90, 103, 112, 114
 - Bovine collagen 112
- C**
- Calcium 91, 111, 112
 - phosphate cement (CPC) 91, 112
 - polyphosphate 111
 - silicate (CS) 112
 - Cardiomyocytes 92, 93
 - Cardiovascular 51
 - events, life-threatening 51
 - risk factors 51
 - Cell 57, 77, 87, 105, 109, 121, 122
 - adhesion 57, 77, 105, 109, 121, 122
 - vascularization 87
 - Cell growth 10, 76, 84, 102, 103, 106, 109, 121
 - microenvironment 121
 - promoting endothelial 10
 - Cell infiltration 51, 108, 116
 - inflammatory 51, 108
 - Cell inoculation 87, 109
 - efficiency 109
 - methods 87
 - Cell proliferation 13, 31, 79, 81, 85, 104, 105, 108
 - endothelial 13
 - Cellular communication patterns 83
 - Chitosan 104, 105, 107
 - cross-linking 105
 - natural biomaterial 107
 - sulfated 107
 - Circulating endothelial progenitor cells (CEPCs) 4, 5, 6, 72
 - Collagen 13, 16, 28, 29, 54, 82, 83, 104, 105, 106, 108, 111, 112, 114
 - complexes 112
 - concentration 28
 - fiber 106
 - gel 114
 - microchannel 114
 - gel layers 83
 - prolyl hydroxylase 54
 - Collagen scaffolds 92, 94, 105, 112
 - fibronectin-containing 92
 - three-dimensional 105
 - Colony-forming cells (CFCs) 2, 4, 94
 - endothelial 94
- D**
- Decomposition 12, 116
 - redundant ECM 12
 - Defects 10, 75, 78, 89, 102, 103, 106, 115
 - cortical bone 75
 - critical size 89

- large-area bone 102, 103
 - rabbit calvarial 78
 - Degradable polymer nanofibers 105
 - Degradation 13, 14, 16, 50, 73, 85, 92, 102, 116, 117, 118, 119, 120
 - adhesive 49
 - destructive effects 16
 - enzymatic 116, 117
 - faster 118, 120
 - limiting PLGA 118
 - local basement membrane 73
 - modes of scaffold 102
 - of ECM proportions 12
 - pathways 116, 120
 - protein 13, 14
 - rapid 92
 - Density 28, 150, 113
 - increased microvessel 50, 113
 - tissue microvessel 113
 - Development of scaffold materials 120
 - Diabetes 6, 48, 72
 - Dielectric electrophoretic 88
 - Diseases 6, 8, 9, 24, 47, 48, 49, 50, 51, 53, 54, 56, 57, 58, 71, 77, 78
 - autoimmune 48
 - cardiovascular 51, 54
 - cerebrovascular 51
 - destructive 47, 48
 - immune 58
 - inflammatory bowel 48
 - lung 53
 - malignant 6, 48
 - orthopaedic 78
 - peripheral arterial 51
 - peripheral artery 56
 - tumor 24
 - ulcerative 6
 - Dynamic 2, 24, 74
 - changes 2
 - process 74
 - structure 24
 - Dysfunction 6, 34, 47, 54, 56, 57
 - endothelial 34, 54
 - mitochondrial 56
 - vascular 47
 - Dyslipidemia 6
- E**
- ECM 11, 24, 25, 85, 86
 - adhesion molecules 11
 - meniscus 86
 - microenvironment 85
 - monolayers 25
 - remodeling 24
 - ECM stiffness 27, 30
 - tension 27
 - varying 30
 - ECs 3, 6, 9, 12, 27, 32, 33, 74, 79
 - and blood cells production 3
 - angiogenetic 12
 - angiogenic 9
 - for graft prevascularization 79
 - growth factors stimulate 74
 - human aortic 27
 - micropatterning 33
 - signalling proteins 32
 - tumor 6
 - Effects 83, 86, 118
 - immunomodulatory 86
 - macrochannel 118
 - neuroinflammatory 83
 - Electrospinning technology 107, 108, 109
 - ELISA method 14
 - Embryoid bodies (EBs) 2, 83, 84
 - Embryonic 2, 3, 79, 81, 84
 - stem cells (ESCs) 2, 3, 79, 81, 84
 - vasculogenesis 2
 - Embryos 1, 3, 6, 47, 72
 - growing mammalian 6
 - Endothelial 1, 4, 6, 15, 26, 27, 70, 72, 79, 80, 90, 113, 114
 - nitric oxide synthase 27
 - progenitor cells (EPCs) 1, 4, 6, 15, 70, 72, 79, 80, 90, 113, 114
 - to-mesenchymal transition 26
 - Endothelial cell(s) (ECs) 2, 7, 9, 10, 11, 13, 14, 24, 27, 28, 32, 51, 55, 56, 57, 79, 80, 91, 92, 93, 94, 113, 114
 - apoptosis 51
 - channels 9
 - death 11
 - development 13
 - growth factors 14
 - in tumour vasculature 57
 - junction 10
 - layer 7
 - Endothelialized tissue-engineered human skin 95
 - Engineering 102, 106, 122

vascular construction 106
 vascularization 102, 122
 process of tissue 102, 122
 vascularization materials 122
 Environment 54, 84, 89, 91
 angiogenesis-promoting 54
 Enzymatic degradation reaction 117
 Enzyme(s) 12, 13, 14, 16, 24, 32, 49, 117,
 119, 120
 fibrinolytic 12
 linked immunosorbent 14
 protein solubilizing 16
 proteolytic 49
 Epidermal growth factor receptor (EGFR) 11
 Expression 3, 8, 16, 27, 31, 50, 52, 58, 79, 86,
 89, 107, 108, 110
 gene 79, 86
 growth factor 89
 mesoembryonic 3
 Extracellular Matrix (ECM) 4, 7, 11, 12, 13,
 24, 25, 26, 27, 71, 74, 84, 85, 88, 104,
 105
 deposition 104
 of vessels 24
 Eye diseases 6, 8
 blinding 6

F

Factors 1, 13, 14, 23, 29, 33, 34, 47, 49, 50,
 54, 55, 74, 85, 87, 91, 116, 118, 120
 adhesion 50, 57
 angiogenesis-promoting 14
 angiogenesis-related 50, 55
 anti-angiogenic 74
 biomechanical 33
 colony-stimulating 50
 dynamic 23
 hemodynamic 34
 pathogenic 54
 pro-angiogenic 91
 pro-inflammatory 49
 Femoral fractures 75
 Fibrin 28, 29, 50, 82, 88, 106, 112
 density 28
 hyrdogels 29
 Fibroblast growth factor (FGFs) 1, 3, 7, 11,
 12, 13, 50, 54, 76
 Fibronectin 13, 14, 25, 28, 73, 106
 fibronectin 14

 polymerization 28
 Fibrosis 24, 112
 Focal adhesions (FAs) 25, 26, 27, 30, 34
 Forces 24, 27, 85
 endogenous 27
 hemodynamic 27
 mechanical 27, 85
 physical 24

G

Gap junction 12, 84
 channels 84
 formation 84
 intercellular communication (GJIC) 12
 Gels 28, 29, 30, 32, 83, 92, 93, 110, 112
 adaptive 110
 agarose 112
 collagen fibronectin 93
 soft collagen 30
 stiffer collagen 28
 three-dimensional fibronectin-collagen 92
 Genes 2, 3, 9, 31, 54, 57, 107, 111
 angiogenesis-related 111
 exogenous 107
 Glycosylation 28
 Grafts 14, 50, 75, 77, 90, 94
 developing pre-vascularized 77
 Granulocyte-macrophage, activating 50
 Growth 8, 9, 10, 11, 13, 14, 16, 32, 47, 48, 51,
 55, 56, 71, 72, 73, 76, 89, 103, 105
 collateral 51
 endothelial 55
 fetal 72
 hormones 56
 organ 48
 tumor 9, 10, 14, 32, 72
 tumour 56

H

Haemorrhagic rupture 58
 Healing 48, 70, 71, 72, 74, 76, 78, 80, 86, 94,
 105
 ability 86
 fracture 80
 normal 76
 rapid 76
 Hemangioblasts 2, 3

Hematopoiesis 2
 Hematopoietic 2, 3, 4
 cells 2, 3, 4
 colonies 3
 lineage 3
 Heparin 13, 14, 107, 108
 binding 14
 molecules 14
 Heterogeneity 86
 HIF-1 downregulates platelet 54
 Homeostasis 8, 52, 54, 77, 89, 114
 oxygen tension 54
 sustaining 77
 vascular 8
 Human 5, 79, 81, 86, 93, 94, 121
 bone marrow stromal cells 121
 dermal fibroblasts (HDFs) 86, 94
 embryonic stem cells 79, 81
 induced pluripotent stem cells 79
 pluripotent stem cells 93
 vascular diseases 5
 Human umbilical cord 78, 79, 81
 perivascular cells 79
 stem cells 78, 81
 Hydrogels 113, 119
 photosensitive 119
 silk fibroin 113
 Hydrolysis 116, 117, 119
 methods 116
 reaction 119
 Hydrolytic degradation 116, 117, 118
 Hydrophobic materials 118
 Hypertension 6, 56, 58
 pulmonary 6, 58
 Hypoglycemia 51
 Hypoxia-inducible factors 49
 Hypoxic 53, 54
 angiogenesis 54
 disease and angiogenesis 53

I

Immunoglobulin superfamily 11
 Impaired angiogenesis 54, 55, 56
 Inflammation 6, 7, 47, 48, 49, 50, 51, 53, 54, 55, 73, 75, 76
 persistent 49
 related diseases and angiogenesis 48, 49
 Inflammatory diseases 47, 48, 49, 50, 58
 chronic 49, 50, 58

 function 49
 Inhibitors 10, 11, 16, 30, 48, 54
 metalloproteinase 16
 plasminogen activator 54
 Integrin 7, 11, 26, 30, 85, 105
 downregulated 30
 pathway 85
 receptor 105
 signaling 7
 Interstitial 5, 16
 collagenase 16
 derived factor 5
 Ischaemia 51, 52, 54, 56
 hypoxic 56
 myocardial 56
 reperfusion injury results 51
 Ischaemia-induced 51, 52
 angiogenesis 52
 deprivation 51
 Ischaemic injury 49, 51, 54
 cerebral 51
 Ischaemic 51, 52, 53
 wound healing 53
 angiogenesis 51, 52
 diseases and angiogenesis 51

K

Keratinocytes 94

L

Lactic acid 104, 116
 dextran 104
 poly-dextran 106
 Lymphatic vessels Circulating 80
 Lymphocytes 50
 Lymphoid lineage 4

M

Macrophage polarization 49
 Macrophages 9, 12, 49, 50, 52, 54, 76, 94
 inflammatory 54
 marrow-derived 52
 tumor-associated 9
 Macrovascular 52, 79
 and microvascular ECs 79
 collateral circulations 52

Malignant infiltration 57
 Matrix metalloproteinase 7, 12, 74
 releasing 74
 Mesenchymal 70, 75, 78, 79, 81, 91, 92, 107,
 113, 115
 precursor cells (MPCs) 92
 stem cells 70, 75, 78, 79, 81, 91, 107, 113,
 115
 Mesoderm 1, 3
 culture 3
 embryonic 3
 extra-embryonic 1
 Metabolic 9, 121
 dynamics 9
 waste 121
 Metabolism 53, 54, 71, 74, 77
 assisting biochemical 77
 energy 53
 nutrient 74
 Microaneurysm formation 10
 Microporous network structure 92
 Microthrombosis 57
 Microtubule-depolymerizing agents 30
 Microvessel 87, 110
 density and maturity 110
 formation efficiency 87
 Migration 11, 13, 14, 27, 29, 32, 34, 48, 49,
 73, 75, 76, 84, 85, 86, 110
 endothelial 13, 76
 Monolayer 82, 83
 mixed cell population 82
 cultures 83
 Morphogenesis 8, 24
 arterial 8
 Multi-directional differentiation potentials 3
 Multi-target 10, 111
 inhibitor, novel 111
 receptor tyrosine kinase inhibitor 10
 Mural cells 9, 10
 vascular 10
 Muscle cells, smooth 3, 11, 52, 71, 75
 Myocardial infarction 5, 6, 51, 58, 72, 80

N

Nano-topological structure 109
 Natural 82, 94, 104, 116
 angiogenesis process 94
 biological scaffolds 104
 high molecular compounds 116

 scaffold materials 104
 tissues 82
 Notch signaling pathway 110

O

Obesity 6, 48, 58, 72
 Occlusion 51, 52, 107
 vascular 51, 52
 Osteogenesis 75, 76, 90, 91, 103, 107, 112,
 121, 122
 process 76
 Outcome of scaffold materials 115
 Oxidative stress 56
 aging-related 56
 increasing 56
 Oxygen 12, 51, 53, 72, 76, 90, 109, 121
 biomaterials 121
 deficiency circumstances 12
 diffusion capacity 109
 tension 53

P

Paracrine signaling 83, 84, 86
 Pathogenesis 48, 58
 Pathogen infection 106
 Pathways 1, 13, 14, 51, 55, 75, 76, 85, 89, 119
 new blood circulation 13, 14
 osteogenic 76
 regulating RhoA-ROCK 85
 Pericyte-deficient murine strains 10
 Peripheral blood (PB) 4, 80, 112, 113, 115
 Perivascular cells 10, 71, 93
 deficient 10
 Permanent endothelial progenitor cells 5
 Permeable cup-shaped device 83
 Phenotypes, cellular 88
 Pigment epithelium-derived factor (PEDF)
 111
 Plasma 14, 16, 57
 enzyme immunoassay 16
 haemorrhagic 57
 Plasminogen activator 16
 Platelet-derived growth factor (PDGF) 1, 3, 9,
 13, 14, 56
 Polymer hydrogels 119
 Polymeric device 116
 Polymer materials 104, 106, 107, 108, 111

- combined artificial synthetic 108
- degradable 104, 106
- non-degradable 106
- synthetic 111
- synthetic biodegradable 104, 106, 107
- synthetic degradable 106, 107
- Postpartum vasculogenesis 4
- Progenitor cells 4, 6, 9, 14, 70, 72, 80, 82
 - capillary plexus via endothelial 70
 - circulating endothelial 4, 72
 - early endothelial 4
 - human umbilical cord blood 82
 - marrow-derived endothelial 9
 - peripheral blood-derived endothelial 80
- Protease(s) 7, 11, 12, 13, 16, 49, 92
 - activity 11
 - inhibitors 12, 92
 - cysteine 16
 - serine 16
- Proteinases 12
- Proteins 3, 7, 16, 26, 27, 29, 30, 56
 - bone morphogenetic 3
 - cytoskeleton-related 29, 30
 - key cytoskeleton 30
 - polymerized 26
- Proteoglycan 13, 26, 106
 - cleavage products 13
- Proteolysis 7, 13, 14
 - degrading 7

R

- Radioimmunoassay 14
- Reaction 10, 14, 106, 119
 - antigen 106
 - catalytic 119
 - enzymatic 119
 - foreign body 119
 - promoting endothelial-mural cell 10
 - strong staining 14
- Reactive oxygen species 51
- Receptors 10, 11, 14, 52, 54
 - epidermal growth factor 11
 - plasminogen activator 54
- Regeneration 5, 6, 70, 71, 74, 76, 81, 82, 91, 92, 93, 109, 113, 119, 121
 - cardiac 70, 91, 92
 - craniofacial 113
 - nerve fiber 113
 - organ 6

- skeletal muscle 81
- skin 70, 76, 81, 93
- vascular 5, 70, 74
- Regenerative medicine technology 23
- Regulating angiogenesis 28
- Regulation 12, 29, 52, 54, 57, 74, 76, 77, 87, 110, 113
 - directional 76
 - osteogenic 87
 - transcriptional 52
- Resting 7
 - ECs processes 7
 - of blood vessels in angiogenesis 7
- Rheumatoid arthritis 47, 48, 49, 50
- Rho 29, 30
 - associated protein kinase 29
 - GTPases 30
 - GTPase signaling balance 29
 - GTPase signals 30
 - signaling 30
- RNA splicing 15

S

- Scaffold-based 110, 113
 - cell complex 113
 - delivery system 110
- Scaffold materials 23, 33, 82, 102, 103, 105, 106, 108, 109, 110, 111, 113, 114, 115, 116, 117, 120, 122
 - acellular matrix 105, 106
 - better vascularization 111
 - biodegradable tubular 108
 - degradation of 116, 120
 - electrospinning 33
 - engineered vascular 108
 - engineering vascular 106
 - hybrid 108
 - pre-programmed degradable 116
 - synthetic 82, 111
 - unimodal 109
 - vascular 108, 113
 - vascularized 111
- Signaling 3, 26, 29, 55, 75, 86
 - remote cell 86
 - cascade 26
 - pathways 3, 29, 55, 75
- Signals 3, 6, 7, 8, 10, 11, 25, 29, 76, 82, 84, 104, 107
 - activin 3


- biomechanical 25
 - connexins 12
 - factors-mediated proliferation 10
 - macrophages release 76
 - paracrine 82
 - release survival 7
 - special biological 104
 - Signal transduction 8, 9, 53
 - anchored 9
 - pathways 53
 - Skin fibroblasts 86, 94
 - human 94
 - Skin grafts 94
 - developing pre-vascularized 94
 - vascularized dermo-epidermal 94
 - SMC-mediated gel shrinkage 93
 - Smooth muscle cells (SMCs) 3, 6, 11, 52, 55, 71, 75, 93, 108, 113, 114
 - Soluble 8, 77, 117
 - biochemical factors 77
 - monomers 117
 - VEGF subtypes 8
 - Sources 5, 50, 78, 79, 80, 81, 86, 92, 93, 113
 - effective 50
 - pericardial 113
 - potential cell 79
 - robust stem cell 79
 - Spiral wound 118, 120
 - sheet 118
 - tablets 120
 - Stem cells 2, 3, 6, 34, 78, 79, 81, 82, 84, 85, 86, 93, 105, 107, 110, 113, 115
 - adipose 113
 - applying human pluripotent 93
 - composite adipose 113
 - cultured embryonic 2
 - embryonic 3, 79, 84
 - endothelial 110
 - fat 105
 - fluid-derived 82, 84, 115
 - gene-transfected mesenchymal 107
 - human adipose-derived 107
 - human mesenchymal 113
 - human synovium-derived 86
 - induced pluripotent 113
 - pluripotent 3
 - synovium-derived 82
 - Stiffness 23, 24, 25, 26, 27, 28, 29, 92, 110
 - gel 29
 - local 25, 26
 - mechanical 28, 92
 - native 26
 - vascular 27
 - Stimulate 11, 12
 - migration 12
 - vasculogenesis 12
 - Stimulating 4, 10, 11, 56, 58, 88
 - bone progenitor cell differentiation 88
 - pericyte accumulation 10
 - vascular growth factor 4
 - Stimulation 3, 6, 10, 48, 70, 88, 89, 90
 - biochemical 88
 - biomechanical 70, 89, 90
 - downstream 3
 - hypoxic 89
 - pathological 48
 - Stimuli-response degradation 116
 - Stress 23, 24, 27, 34, 52, 74
 - loading 34
 - residual hoop 24
 - traction 27
 - Stress fibers 27, 30
 - actin 27, 30
 - organized 30
 - Stroke 51, 56
 - Stromal cells 8, 9, 83
 - murine 83
 - Structural 57, 89, 108
 - defects 57
 - features 89
 - integrity 108
 - Structured secondary stage 2
 - Structures 28, 70, 75, 79, 80, 82, 91, 92, 93, 94, 95, 116, 120, 122
 - micro-columnar 122
 - Substance produced by angiogenesis 16
 - Surface erosion 116, 117
 - reaction 117
 - Synovium-derived stem cells (SDSCs) 82, 86
 - Systems 24, 29, 74, 76, 81, 82, 83, 84, 90
 - circulatory 90
 - glycated collagen gel 29
 - immune 76
 - local microvascular 74
 - microvasculature 24
 - single-culture EC 90
- T**
- Target cells 77, 78, 84, 86, 90

- regulating 86
 - Technology 33, 77, 79, 102, 105, 109, 121
 - cell slicing 33
 - engineering 102
 - engineering manufacturing 121
 - free cell sheet 121
 - freeze-drying 105
 - fused deposition molding 121
 - gene reprogramming 79
 - light patterning 33
 - medical 109
 - multidisciplinary transformational 77
 - three-dimensional fiber deposition 33
 - Tension 27, 29, 30, 55, 85
 - actomyosin 29
 - balancing cytoskeletal 85
 - intracellular 85
 - strong 30
 - vascular 55
 - Tetrahedral DNA nanostructure 110
 - Therapy 10, 15, 24, 72
 - anti-angiogenic 15
 - cell-based support 24
 - multi-target 10
 - Three-dimensional 13, 29, 105
 - fibrin structure 29
 - structure 13, 105
 - Thrombopoietin 82, 83
 - Thrombosis 51, 107
 - arterial 51
 - Tissue 7, 70, 74, 77, 78, 79, 80, 86, 89, 103
 - functions 77
 - growth 86, 103
 - inhibitors of metalloproteins 7
 - matrix 77
 - oxygenation 74
 - regeneration 70, 74, 78, 79, 80, 89
 - remodeling 89
 - Tissue engineering 23, 102, 103, 110, 122
 - major factors of 102, 122
 - biological scaffold materials 103
 - strategy 110
 - vascularization 23, 102
 - Topological structure 109, 122
 - of scaffold material 109
 - spatial 109
 - Transcription factor 3, 52
 - hypoxia-induced 52
 - Transmission 104, 105
 - pathogen 105
 - Transplantation 23, 32, 108, 114, 115
 - direct orthotopic 115
 - organ 32
 - therapy 23
 - Transport 47, 48, 72, 74
 - oxygen 47, 48, 74
 - proteins 72
 - Trauma 23, 52, 57, 77, 119
 - related symptoms 57
 - repair tissue 23
 - Tumor-associated macrophages (TAMs) 9, 49
 - Tumorigenesis 79
 - Tumorigenicity 79
 - Tunable biodegradation cycle 106
 - Type IV collagenase 16
 - Tyrosine kinase inhibitor (TKIs) 10
- ## U
- Umbilical cord blood (UCB) 4, 78, 80, 82
- ## V
- Vascular 6, 8, 11, 12, 23, 24, 25, 29, 50, 51, 55, 56, 72, 86, 91, 93, 94, 108, 113, 114
 - aberrance 8
 - abruption 11
 - anastomosis 50
 - assembly 25
 - border 6
 - completion 11
 - development 8, 11, 12, 55
 - diseases 24, 51
 - dysfunction manifests 72
 - smooth muscle cells (VSMCs) 6, 11, 55, 86, 93, 108, 113, 114
 - stratification 56
 - structures 23, 29, 91, 94
 - Vascular endothelial growth factor (VEGF) 1, 3, 7, 8, 9, 10, 11, 12, 14, 49, 50, 51, 52, 54, 74, 75, 94, 107, 110, 111
 - gene 107
 - releasing 107
 - Vascular growth 6, 8, 47, 48, 51, 52, 89, 94
 - abnormal 6
 - excessive 52
 - factor, critical 94
 - insufficient 48
 - Vascularization 13, 33, 76, 102, 114, 121

- axial 121
- engineering tissue 114
- fast 121
- functional 33
- in wound healing 76
- process 13, 102
- Vascular network 1, 27, 29, 30, 32
 - formation 27, 29, 30, 32
 - remodeling 1
- Vascular networks 24, 28, 29, 30, 34, 70, 71, 72, 74, 75, 76, 86, 92, 94, 95, 112, 113, 114, 115
 - construction of 1, 112
 - endothelial 95
 - existing organized 34
 - organized functional 34
 - stable 28, 92, 112
 - transplanted 72
- Vascular stent materials 103, 104, 108, 112, 122
 - printed 112
 - tissue-engineered 108
- Vascular substitutes 108
 - engineered 108
 - small-bore 108
- Vasculogenesis 1, 2, 5, 12, 51, 70, 71, 72
 - atmosphere 12
 - granulation tissue 5
 - in reparative process 5
- Vasodilation 6, 8, 56, 108
 - pathological 6
- VEGF 10, 12, 50, 52
 - blockade of 10
 - expression of 50, 52
 - matrix-bound 12
- Veins 3, 8, 56, 71, 72, 114, 115
 - cavity 71
 - derived angiogenesis of arterial branch 8
 - ECs origin form, isolating 8
 - small 56, 72
- Ventricular ejection fraction, left 113
- Vessel 6, 30, 51
 - chamber 51
 - differentiation 6
 - integrity 30
- Vessel walls 24, 32, 72, 74
 - injured 72
 - remodel 74

W

- Wound healing 5, 32, 49, 50, 52, 72, 76, 88
 - permanent 72
 - site 5
 - therapies 76
- Wound repair 52, 76, 88, 94, 105
 - accelerating 94
 - normal 88



Xiaoxiao Cai

Xiaoxiao Cai, D.D.S., M.D., Ph.D., is a full professor at the West China School of Stomatology, Sichuan University. She serves as the vice-director of Dental Implant Center, West China School of Stomatology. She received her D.D.S, M.D. and Ph.D. from Sichuan University in 2010. Dr. Cai's research focuses on adipose stem cell differentiation and vascularization of craniofacial regeneration, such as bone, cartilage, tooth, fat, etc. She has published over 75 first author or corresponding author papers, reviews and book chapters, and made several seminal contributions to the stem cell fields. She has served as an associate editor of *Nanoscience and Nanotechnology Letters* (SCI) and as an editor of *Cell Proliferation* (SCI). She received Excellent Doctoral Dissertation of Sichuan Province and Nomination of National Excellent Doctoral Dissertation of China.